Anteris Technologies Global Corp. (ASX:AVR) Updates Market on Court Orders and CDI Matter Resolution

Anjali Anand

11 August 2026 11:18 PM AEST

Anteris Technologies Global Corp. (ASX:AVR) Updates Market on Court Orders and CDI Matter Resolution

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Anteris Technologies Global Corp. (ASX:AVR) received Federal Court of Australia orders relating to an administrative oversight involving CDI cleansing notice lodgement.
The company requested the lifting of the Trading halt effective from market open on 4 August 2026.
The Court orders addressed the treatment of 44,068 CHESS Depositary Interests issued on 10 July 2026.
Anteris operates in the structural heart medical technology sector, focusing on device development.
AVR shares were trading at $12.550, with a Market Capitalisation of $1.17B based on provided market data.

Anteris Technologies Provides Update on Federal Court Proceedings

Anteris Technologies Global Corp. (ASX:AVR) announced that the Federal Court of Australia granted the relief sought by the company regarding an administrative matter associated with the late lodgement of a cleansing notice under the Corporations Act 2001 (Cth).

The company had previously applied to the Federal Court to rectify an inadvertent administrative oversight related to the lodgement timing of the notice. Following the hearing on 3 August 2026, the Court granted the requested orders.

The announcement stated that Anteris requested the ASX trading halt on its securities to be lifted from market open on 4 August 2026. The company also provided a copy of the Court orders as part of the announcement process.

Details of the Court Orders

The Federal Court orders related specifically to 44,068 CHESS Depositary Interests (CDIs) issued by Anteris on 10 July 2026. The Court extended the relevant period under section 708A(6)(a) of the Corporations Act 2001 (Cth) to 31 July 2026.

The orders also declared that the cleansing notice provided to the Australian Securities Exchange within the extended period would take effect as though it had been provided on 10 July 2026.

Further, the Court declared that any sale or offer for sale of the impacted CDIs during the period after their issuance until the date of the order would not be invalid due to the timing issue relating to the cleansing notice.

The Court also granted relief relating to potential civil Liability connected with the administrative oversight for persons involved with the impacted CDIs.

Anteris Share Market Information

Based on the provided market data, Anteris Technologies Global Corp. (ASX:AVR) was trading at $12.550, representing an increase of $0.540 or 4.496%. The company recorded trading Volume of 37,479 shares, with a market capitalisation of $1.17B.

The stock traded within a daily range of $12.000 to $12.550, compared with the previous close of $12.010. The provided 52-week trading range was between $5.200 and $15.470.

Anteris has 97,458,474 shares on issue, with its ASX-listed securities structured as Chess Depositary Interests on a 1:1 basis. The company’s ISIN is AU0000088841.

Company Overview and Medical Technology Focus

Anteris Technologies Global Corp. operates as a medical technology company focused on structural heart solutions. The company is listed on both the Australian Securities Exchange under ASX:AVR and the Nasdaq under AVR.

The company’s activities are centred on designing and developing medical devices intended to support the treatment of structural heart conditions. Anteris’ operations are based across locations including Brisbane, Minneapolis, Geneva and Malaga.

The company’s product development activities include the DurAVR Transcatheter Heart Valve (THV) System, which is being developed as part of its structural heart technology platform. (ASX: AVR">Anteris Technologies)

Regulatory and Corporate Developments

The Federal Court application was related to a compliance process associated with securities issued by the company. The Court’s orders provided a framework to address the administrative timing issue associated with the cleansing notice.

Following the Court decision, Anteris confirmed that the company would provide the sealed orders to relevant parties, including the Australian Securities and Investments Commission (ASIC), ASX and affected CDI holders. The company also stated that the orders would remain available on its website for at least 28 days.

The announcement represented a corporate update regarding securities administration rather than an operational update on the company’s medical technology programs.

Business Activities and Development Programs

Anteris operates within the medical device sector, with a focus on structural heart technology development. The company has previously provided updates regarding the development of its DurAVR THV System and related clinical activities. (Anteris Technologies)

The company’s activities include clinical, regulatory and Manufacturing programs associated with advancing its medical device technologies. Earlier company updates have included progress related to clinical trial activities and regulatory processes connected with its technology platform.

Market Focus Following Court Update

The latest announcement provides clarity on the CDI administrative matter and outlines the actions taken following the Federal Court decision. For investors and Market Participants tracking ASX:AVR, the update provides information regarding the status of the impacted securities and the company’s response to the administrative issue.

Future company announcements will provide further information regarding operational developments, clinical programs and financial updates as they become available through official disclosures.

Conclusion

Anteris Technologies Global Corp. (ASX:AVR) has provided an update regarding Federal Court orders connected with an administrative oversight involving CDI cleansing notice lodgement. The Court granted the requested relief, addressing the treatment of 44,068 impacted CDIs issued on 10 July 2026. The company also requested the lifting of the trading halt from 4 August 2026. The announcement provides information on the resolution process for the securities matter, while further operational updates will depend on future company disclosures.

FAQs

Q: What is the ASX ticker code for Anteris Technologies Global Corp.?

A:Anteris Technologies Global Corp. is listed on the Australian Securities Exchange under the ticker ASX:AVR.

Q: What was the Federal Court matter related to?

A:The Federal Court matter related to an inadvertent administrative oversight involving the late lodgement of a cleansing notice under the Corporations Act 2001 (Cth).

Q: How many CHESS Depositary Interests were covered by the Court orders?

A:The Court orders applied to 44,068 CHESS Depositary Interests issued on 10 July 2026.

Q: When did Anteris request the trading halt to be lifted?

A:Anteris requested the trading halt to be lifted effective from market open on 4 August 2026.

Q: Does this article provide financial advice about Anteris Technologies Global Corp.?

A:No. This article is intended for general educational purposes only and does not provide financial advice, valuation, or any recommendation regarding securities.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.